Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

Background Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non‐small‐cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second‐line treatment after chemoimmunotherapy is cruc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thoracic cancer 2022-01, Vol.13 (2), p.173-181
Hauptverfasser:	Ishida, Masaki, Morimoto, Kenji, Yamada, Tadaaki, Shiotsu, Shinsuke, Chihara, Yusuke, Yamada, Takahiro, Hiranuma, Osamu, Morimoto, Yoshie, Iwasaku, Masahiro, Tokuda, Shinsaku, Takeda, Takayuki, Takayama, Koichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy chemoimmunotherapy Chemotherapy Docetaxel - therapeutic use docetaxel plus ramucirumab Female Humans Immunotherapy Immunotherapy - methods Ligands Lung cancer Lung Neoplasms - drug therapy Male Medical prognosis Metastasis Middle Aged Monoclonal antibodies Mutation Neutrophils non‐small‐cell lung cancer Original Patients performance status Ramucirumab Retrospective Studies Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non‐small‐cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second‐line treatment after chemoimmunotherapy is crucial for improving clinical outcomes. Methods Of 88 enrolled patients with advanced NSCLC who received chemoimmunotherapy, we retrospectively evaluated 33 who received second‐line chemotherapy after progression of chemoimmunotherapy at six centers in Japan. Among them, 18 patients received docetaxel plus ramucirumab and 15 patients received single‐agent chemotherapy. Results The objective response rate in patients treated with docetaxel plus ramucirumab was significantly higher than that in patients treated with a single‐agent chemotherapy regimen (55.6% vs. 0%, p
ISSN:	1759-7706 1759-7714
DOI:	10.1111/1759-7714.14236